Insiders and Institutional Investors Selling Eli Lilly & Co.’s Stock in Q3

Insiders are generally long-term investors due to restriction in making short-term profits. In contrast, wealth management institutions always have short-term investment. Wall St. Watchdog reveals information regarding the insiders and institutions which recently decreased stock shares of Eli Lilly & Co. (NYSE:LLY).

SEC data indicate these insiders have sold Eli Lilly & Co.’s stock since 06/30/2011:

  • Carmine Bryce D.: act as EVP and Pres, Lilly Bio-Meds. On 10/11/2011, sold 5,700 shares, worth $217,200.
  • Carmine Bryce D.: act as EVP and Pres, Lilly Bio-Meds. On 11/11/2011, sold 5,700 shares, worth $214,000.
  • Carmine Bryce D.: act as EVP and Pres, Lilly Bio-Meds. On 07/11/2011, sold 5,700 shares, worth $213,100.
  • Carmine Bryce D.: act as EVP and Pres, Lilly Bio-Meds. On 09/12/2011, sold 5,700 shares, worth $204,700.
  • Carmine Bryce D.: act as EVP and Pres, Lilly Bio-Meds. On 08/11/2011, sold 5,700 shares, worth $193,500.

SEC data indicate that these institutions significantly reduced their stock shares of Eli Lilly & Co. in Q3 2011:

  • HGK ASSET MANAGEMENT INC: On 06/30/2011, held 1,178,213 shares, worth $43,028,339. On 09/30/2011, held 0 shares.
  • SEMINOLE MANAGEMENT CO. INC.: On 06/30/2011, held 567,822 shares, worth $20,736,859. On 09/30/2011, held 0 shares.
  • EMPLOYEES RETIREMENT SYSTEM OF TEXAS: On 06/30/2011, held 532,064 shares, worth $19,430,977. On 09/30/2011, held 0 shares.
  • MARSHALL & ILSLEY CORP: On 06/30/2011, held 473,875 shares, worth $17,305,915. On 09/30/2011, held 0 shares.
  • TD SECURITIES (USA) LLC: On 06/30/2011, held 290,582 shares, worth $10,612,055. On 09/30/2011, held 0 shares.

About the company: Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products for humans and animals. The Company’s products are sold in countries around the world. Eli Lilly’s products include neuroscience products, endocrine products, anti-infectives, cardiovascular agents, oncology products, and animal health products.

Competitors to Watch: Pfizer Inc. (NYSE:PFE), Bristol Myers Squibb Co. (NYSE:BMY), Merck & Co., Inc. (NYSE:MRK), Johnson & Johnson (NYSE:JNJ), Amylin Pharmaceuticals, Inc. (NASDAQ:AMLN), GlaxoSmithKline plc (NYSE:GSK), Alkermes, Inc. (NASDAQ:ALKS), Novartis AG (NYSE:NVS), and Abbott Laboratories (NYSE:ABT).

(Note: Data regarding Eli Lilly & Co.’s stock holdings are sourced from whalewisdom.com. All data are assumed to be accurate.)

Advantage: Check out our interactive stock charts, fundamentals, Twitter stream, and more >>

Improve Your 2011 Financial Health: Join the winning team of stock pickers with Wall St. Cheat Sheet’s acclaimed premium newsletter>>